vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and TripAdvisor, Inc. (TRIP). Click either name above to swap in a different company.
TripAdvisor, Inc. is the larger business by last-quarter revenue ($411.0M vs $247.1M, roughly 1.7× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -9.2%, a 20.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 0.0%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-122.0M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Tripadvisor is an American company that operates online travel agencies, comparison shopping websites, and mobile apps with user-generated content.
ANIP vs TRIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $411.0M |
| Net Profit | $27.5M | $-38.0M |
| Gross Margin | — | 91.5% |
| Operating Margin | 14.1% | -8.3% |
| Net Margin | 11.1% | -9.2% |
| Revenue YoY | 29.6% | 0.0% |
| Net Profit YoY | 367.5% | -3900.0% |
| EPS (diluted) | $1.14 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $411.0M | ||
| Q3 25 | $227.8M | $553.0M | ||
| Q2 25 | $211.4M | $529.0M | ||
| Q1 25 | $197.1M | $398.0M | ||
| Q4 24 | $190.6M | $411.0M | ||
| Q3 24 | $148.3M | $532.0M | ||
| Q2 24 | $138.0M | $497.0M | ||
| Q1 24 | $137.4M | $395.0M |
| Q4 25 | $27.5M | $-38.0M | ||
| Q3 25 | $26.6M | $53.0M | ||
| Q2 25 | $8.5M | $36.0M | ||
| Q1 25 | $15.7M | $-11.0M | ||
| Q4 24 | $-10.3M | $1.0M | ||
| Q3 24 | $-24.2M | $39.0M | ||
| Q2 24 | $-2.3M | $24.0M | ||
| Q1 24 | $18.2M | $-59.0M |
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 92.6% | ||
| Q2 25 | — | 92.1% | ||
| Q1 25 | — | 93.2% | ||
| Q4 24 | — | 93.4% | ||
| Q3 24 | — | 92.5% | ||
| Q2 24 | — | 92.8% | ||
| Q1 24 | — | 93.7% |
| Q4 25 | 14.1% | -8.3% | ||
| Q3 25 | 15.9% | 12.7% | ||
| Q2 25 | 6.6% | 11.2% | ||
| Q1 25 | 13.3% | -3.8% | ||
| Q4 24 | -2.3% | 0.2% | ||
| Q3 24 | -13.8% | 13.2% | ||
| Q2 24 | 3.7% | 7.2% | ||
| Q1 24 | 14.8% | -3.8% |
| Q4 25 | 11.1% | -9.2% | ||
| Q3 25 | 11.7% | 9.6% | ||
| Q2 25 | 4.0% | 6.8% | ||
| Q1 25 | 8.0% | -2.8% | ||
| Q4 24 | -5.4% | 0.2% | ||
| Q3 24 | -16.3% | 7.3% | ||
| Q2 24 | -1.7% | 4.8% | ||
| Q1 24 | 13.2% | -14.9% |
| Q4 25 | $1.14 | $-0.32 | ||
| Q3 25 | $1.13 | $0.43 | ||
| Q2 25 | $0.36 | $0.28 | ||
| Q1 25 | $0.69 | $-0.08 | ||
| Q4 24 | $-0.45 | $0.03 | ||
| Q3 24 | $-1.27 | $0.27 | ||
| Q2 24 | $-0.14 | $0.17 | ||
| Q1 24 | $0.82 | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $1.0B |
| Total DebtLower is stronger | — | $819.0M |
| Stockholders' EquityBook value | $540.7M | $645.0M |
| Total Assets | $1.4B | $2.6B |
| Debt / EquityLower = less leverage | — | 1.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $1.0B | ||
| Q3 25 | $262.6M | $1.2B | ||
| Q2 25 | $217.8M | $1.2B | ||
| Q1 25 | $149.8M | $1.2B | ||
| Q4 24 | $144.9M | $1.1B | ||
| Q3 24 | $145.0M | $1.1B | ||
| Q2 24 | $240.1M | $1.2B | ||
| Q1 24 | $228.6M | $1.2B |
| Q4 25 | — | $819.0M | ||
| Q3 25 | — | $821.0M | ||
| Q2 25 | — | $822.0M | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $831.0M | ||
| Q3 24 | — | $832.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $645.0M | ||
| Q3 25 | $505.8M | $707.0M | ||
| Q2 25 | $436.8M | $627.0M | ||
| Q1 25 | $418.6M | $643.0M | ||
| Q4 24 | $403.7M | $943.0M | ||
| Q3 24 | $405.9M | $944.0M | ||
| Q2 24 | $455.8M | $857.0M | ||
| Q1 24 | $452.0M | $825.0M |
| Q4 25 | $1.4B | $2.6B | ||
| Q3 25 | $1.4B | $2.8B | ||
| Q2 25 | $1.3B | $2.9B | ||
| Q1 25 | $1.3B | $2.8B | ||
| Q4 24 | $1.3B | $2.6B | ||
| Q3 24 | $1.3B | $2.7B | ||
| Q2 24 | $920.8M | $2.8B | ||
| Q1 24 | $914.5M | $2.7B |
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | — | 1.31× | ||
| Q1 25 | — | 1.81× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-103.0M |
| Free Cash FlowOCF − Capex | $29.1M | $-122.0M |
| FCF MarginFCF / Revenue | 11.8% | -29.7% |
| Capex IntensityCapex / Revenue | 0.5% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $163.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-103.0M | ||
| Q3 25 | $44.1M | $44.0M | ||
| Q2 25 | $75.8M | $202.0M | ||
| Q1 25 | $35.0M | $102.0M | ||
| Q4 24 | $15.9M | $-3.0M | ||
| Q3 24 | $12.5M | $-43.0M | ||
| Q2 24 | $17.4M | $51.0M | ||
| Q1 24 | $18.3M | $139.0M |
| Q4 25 | $29.1M | $-122.0M | ||
| Q3 25 | $38.0M | $25.0M | ||
| Q2 25 | $71.8M | $177.0M | ||
| Q1 25 | $32.5M | $83.0M | ||
| Q4 24 | $13.5M | $-26.0M | ||
| Q3 24 | $7.7M | $-63.0M | ||
| Q2 24 | $13.0M | $36.0M | ||
| Q1 24 | $13.7M | $123.0M |
| Q4 25 | 11.8% | -29.7% | ||
| Q3 25 | 16.7% | 4.5% | ||
| Q2 25 | 34.0% | 33.5% | ||
| Q1 25 | 16.5% | 20.9% | ||
| Q4 24 | 7.1% | -6.3% | ||
| Q3 24 | 5.2% | -11.8% | ||
| Q2 24 | 9.4% | 7.2% | ||
| Q1 24 | 10.0% | 31.1% |
| Q4 25 | 0.5% | 4.6% | ||
| Q3 25 | 2.7% | 3.4% | ||
| Q2 25 | 1.9% | 4.7% | ||
| Q1 25 | 1.3% | 4.8% | ||
| Q4 24 | 1.3% | 5.6% | ||
| Q3 24 | 3.2% | 3.8% | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 3.3% | 4.1% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 0.83× | ||
| Q2 25 | 8.87× | 5.61× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | -3.00× | ||
| Q3 24 | — | -1.10× | ||
| Q2 24 | — | 2.13× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TRIP
| Third Party | $327.0M | 80% |
| The Fork | $58.0M | 14% |
| Other | $26.0M | 6% |
